+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Necrotizing Enterocolitis - Pipeline Insight, 2021

  • ID: 5262004
  • Clinical Trials
  • February 2021
  • Region: Global
  • 60 Pages
  • DelveInsight

FEATURED COMPANIES

  • Leadiant Biosciences
  • Noveome
This “Necrotizing Enterocolitis - Pipeline Insight, 2021,” report provides comprehensive insights about 4+ companies and 4+ pipeline drugs in Necrotizing Enterocolitis pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

  • Global coverage

Necrotizing Enterocolitis Understanding


Necrotizing Enterocolitis: Overview


Necrotizing enterocolitis (NEC), which typically occurs in the second to third week of life in premature, formula-fed infants, is characterized by variable damage to the intestinal tract, ranging from mucosal injury to full-thickness necrosis and perforation. In severe cases of NEC, a hole may form in the wall of the intestine. If this occurs, the bacteria normally found inside the intestine can leak into the abdomen and cause widespread infection. This is considered a medical emergency.

"Necrotizing Enterocolitis - Pipeline Insight, 2021" report outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Necrotizing Enterocolitis pipeline landscape is provided which includes the disease overview and Necrotizing Enterocolitis treatment guidelines. The assessment part of the report embraces, in depth Necrotizing Enterocolitis commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Necrotizing Enterocolitis collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

  • The companies and academics are working to assess challenges and seek opportunities that could influence Necrotizing Enterocolitis R&D. The therapies under development are focused on novel approaches to treat/improve Necrotizing Enterocolitis.

Necrotizing Enterocolitis Emerging Drugs Chapters


This segment of the Necrotizing Enterocolitis report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Necrotizing Enterocolitis Emerging Drugs

  • IBP-9414: Infant Bacterial Therapeutics
IBP-9414 for the prevention of necrotizing enterocolitis (NEC) contains the active substance Lactobacillus reuteri, which is a co-evolved human bacterial strain naturally present in breast milk. Lactobacillus reuteri is a live bacteria known to be anti-inflammatory, anti-pathogenic and beneficial to gut motility. In June 2016, IBT commenced the Safety and Tolerability study. In late 2017, the results demonstrated a similar safety and tolerability profile in the active group as in the placebo group. The pivotal Phase III study, the Connection study, commenced July 4, 2019.
  • STP-206: Leadiant Biosciences
Mechanism of Action is Bacteria replacements. The drug is currently in phase 2 of clinical trials for the treatment of Necrotizing Enterocolitis.

Necrotizing Enterocolitis: Therapeutic Assessment


This segment of the report provides insights about the different Necrotizing Enterocolitis drugs segregated based on following parameters that define the scope of the report, such as:


Major Players in Necrotizing Enterocolitis


There are approx. 4+ key companies which are developing the therapies for Necrotizing Enterocolitis. The companies which have their Necrotizing Enterocolitis drug candidates in the most advanced stage, i.e. phase III include, Infant Bacterial Therapeutics Biopharma.

The report covers around 4+ products under different phases of clinical development like

  • Late stage products (Phase III)
  • Mid-stage products (Phase II)
  • Early-stage product (Phase I) along with the details of
  • Pre-clinical and Discovery stage candidates
  • Discontinued & Inactive candidates

Route of Administration

Necrotizing Enterocolitis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

  • Oral
  • Parenteral
  • intravitreal
  • Subretinal
  • Topical.
  • Molecule Type

Products have been categorized under various Molecule types such as

  • Monoclonal Antibody
  • Peptides
  • Polymer
  • Small molecule
  • Gene therapy
  • Product Type

The drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Necrotizing Enterocolitis: Pipeline Development Activities


The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Necrotizing Enterocolitis therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities


The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Necrotizing Enterocolitis drugs.

Necrotizing Enterocolitis Report Insights

  • Necrotizing Enterocolitis Pipeline Analysis
  • Therapeutic Assessment
  • Unmet Needs
  • Impact of Drugs

Necrotizing Enterocolitis Report Assessment

  • Pipeline Product Profiles
  • Therapeutic Assessment
  • Pipeline Assessment
  • Inactive drugs assessment
  • Unmet Needs

Key Questions Answered


Current Treatment Scenario and Emerging Therapies:

  • How many companies are developing Necrotizing Enterocolitis drugs?
  • How many Necrotizing Enterocolitis drugs are developed by each company?
  • How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Necrotizing Enterocolitis?
  • What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Necrotizing Enterocolitis therapeutics?
  • What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
  • What are the clinical studies going on for Necrotizing Enterocolitis and their status?
  • What are the key designations that have been granted to the emerging drugs?

Key Players

  • Infant Bacterial Therapeutics
  • Leadiant Biosciences
  • Noveome

Key Products

  • IBP-9414
  • STP-206
  • ST 266
Note: Product cover images may vary from those shown

FEATURED COMPANIES

  • Leadiant Biosciences
  • Noveome

IntroductionExecutive Summary
Necrotizing Enterocolitis: Overview
  • Causes
  • Mechanism of Action
  • Signs and Symptoms
  • Diagnosis
  • Disease Management

Pipeline Therapeutics
  • Comparative Analysis

Therapeutic Assessment
  • Assessment by Product Type
  • Assessment by Stage and Product Type
  • Assessment by Route of Administration
  • Assessment by Stage and Route of Administration
  • Assessment by Molecule Type
  • Assessment by Stage and Molecule Type

Necrotizing Enterocolitis - Analytical Perspective
In-depth Commercial Assessment
  • Necrotizing Enterocolitis companies' collaborations, Licensing, Acquisition - Deal Value Trends

Necrotizing Enterocolitis Collaboration Deals
  • Company-Company Collaborations (Licensing / Partnering) Analysis
  • Company-University Collaborations (Licensing / Partnering) Analysis

Late Stage Products (Phase III)
  • Comparative Analysis

IBP-9414: Infant Bacterial Therapeutics
  • Product Description
  • Research and Development
  • Product Development Activities

Mid Stage Products (Phase II)
  • Comparative Analysis

STP-206: Leadiant Biosciences
  • Product Description
  • Research and Development
  • Product Development Activities

Inactive Products
  • Comparative Analysis

Necrotizing Enterocolitis Key CompaniesNecrotizing Enterocolitis Key ProductsNecrotizing Enterocolitis - Unmet NeedsNecrotizing Enterocolitis - Market Drivers and BarriersNecrotizing Enterocolitis - Future Perspectives and ConclusionNecrotizing Enterocolitis Analyst ViewsNecrotizing Enterocolitis Key CompaniesAppendix
List of Tables
Table 1 Total Products for Necrotizing Enterocolitis
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products
List of Figures
Figure 1 Total Products for Necrotizing Enterocolitis
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products
Note: Product cover images may vary from those shown

A selection of companies mentioned in this report includes:

  • Infant Bacterial Therapeutics
  • Leadiant Biosciences
  • Noveome
Note: Product cover images may vary from those shown